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B cell activation factor of the TNF family (BAFF/BLyS), an essential B cell survival factor
of which circulating levels are elevated in several autoimmune disorders, is targeted in
the clinic for the treatment of systemic lupus erythematosus (SLE). The soluble form
of BAFF can exist as 3-mer, or as 60-mer that results from the ordered assembly of
twenty 3-mers and that can be obtained from naturally cleaved membrane-bound BAFF
or made as a recombinant protein. However, which forms of soluble BAFF exist and
act in humans is unclear. In this study, BAFF 3-mer and 60-mer in biological fluids
were characterized for size, activity and response to specific stimulators or inhibitors
of BAFF. Human cerebrospinal fluids (CSF) from patients with multiple sclerosis and
adult human sera contained exclusively BAFF 3-mer in these assays, also when BAFF
concentrations were moderately SLE or highly (BAFFR-deficient individual) increased.
Human sera, but not CSF, contained a high molecular weight, saturable activity that
dissociated preformed recombinant BAFF 60-mer into 3-mer. This activity was lower
in cord blood. Cord blood displayed BAFF levels 10-fold higher than in adults and
consistently contained a fair proportion of active high molecular weight BAFF able to
dissociate into 3-mer but not endowed with all properties of recombinant BAFF 60-
mer. If BAFF 60-mer is produced in humans, it is dissociated, or at least attenuated in
the circulation.
Keywords: B-cell activating factor, cerebrospinal fluid, serum, cord blood, 60-mer, atacicept, belimumab
Abbreviations: BAFF, B cell activating factor of the TNF family; APRIL, A proliferation-inducing ligand; BAFFR, BAFF
receptor; TACI, Transmembrane activator and CAML interactor; BCMA, B cell maturation antigen; SLE, systemic lupus
erythematosus; CVID, common variable immunodeficiency; MS, multiple sclerosis; SEC, size exclusion chromatography;
CSF, cerebrospinal fluid; FCS, fetal calf serum; BSA, bovine serum albumin.
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INTRODUCTION
B cell activating factor (BAFF), a member of TNF family ligands,
is a factor for the survival and development of B cells, as
evidenced by the sharp reduction of peripheral B cells in BAFF-
deficient mice (Schiemann et al., 2001; Craxton et al., 2005;
Mackay and Schneider, 2009). Like other TNF family ligands,
BAFF is a type II membrane-bound protein. It is expressed
by cell types like macrophages, dendritic cells, neutrophils
and monocytes, but also by stromal cells like astrocytes or
carcinoma cells (Mackay et al., 2003; Krumbholz et al., 2005; Kato
et al., 2006; Giordano et al., 2020). BAFF can be proteolytically
processed by furin to release a soluble trimeric ligand, or
can remain membrane-bound (Craxton et al., 2003; Bossen
and Schneider, 2006). BAFF binds to three different receptors:
BAFFR (BAFF receptor), TACI (transmembrane activator and
CAML interactor) and BCMA (B cell maturation antigen), which
are expressed on B lineage cells at different stages of their
development (Bossen and Schneider, 2006). BAFF can form
biologically active heteromers with A proliferation inducing
ligand (APRIL), a related member of the TNF family (Hahne
et al., 1998). Heteromers were first detected in the serum
of patients with rheumatic diseases (Roschke et al., 2002).
APRIL and BAFF-APRIL heteromers share with BAFF the two
receptors TACI and BCMA (Schuepbach-Mallepell et al., 2015).
BAFF activates non-canonical and/or canonical NF-κB pathways
(Claudio et al., 2002; Hatada et al., 2003), which upregulate anti-
apoptotic factors like Mcl-1 to improve B lymphocyte survival
[reviewed in Mackay and Schneider (2009)]. Similar to the
TNF system, in which soluble TNF is the prime activating
ligand for TNFR1 while membrane-bound TNF more specifically
stimulates TNFR2 (Grell et al., 1995), BAFF and APRIL receptors
may respond differently to various forms of ligands. In vitro data
indicate that, unlike BAFFR, TACI does not respond to the action
of trimeric BAFF or APRIL, but requires higher order oligomers
of these ligands to become activated efficiently (Bossen et al.,
2008). These oligomers may mimic the action of membrane-
bound ligands.
Circulating BAFF levels are elevated in patients with systemic
lupus erythematosus (SLE; Zhang et al., 2001; McCarthy et al.,
2013; Salazar-Camarena et al., 2016), multiple sclerosis (MS;
Kannel et al., 2015; Steri et al., 2017), rheumatoid arthritis
(Cheema et al., 2001), or IgA nephropathy (Xin et al., 2013; Li
et al., 2014). A genetic variant of BAFF, enriched in Sardinia,
results in elevated serum levels of BAFF and is associated with
a risk for MS (Steri et al., 2017). Outside of Sardinia, serum
levels of BAFF were found to be elevated in some (Kannel et al.,
2015), but not all (Krumbholz et al., 2008) studies, but were
consistently found to be elevated in response to IFN-β therapy
(Krumbholz et al., 2008; Kannel et al., 2015) and rituximab
(Pellkofer et al., 2008). Additionally, genetic alterations in BAFFR
or TACI genes can lead to common variable immunodeficiency
(CVID) which is characterized by hypogammaglobulinemia and
recurrent respiratory or intestinal tract infections (Rosen et al.,
1999; Warnatz et al., 2009). Individuals with BAFFR deficiency
show defective B cell development and lower level of IgM and
IgG. In contrast, circulating levels of BAFF are higher than in
controls by one to two orders of magnitude (Warnatz et al., 2009;
Kreuzaler et al., 2012). All receptors for BAFF and APRIL can
be processed to soluble forms (Hoffmann et al., 2015; Laurent
et al., 2015; Smulski et al., 2017). Soluble TACI and BCMA were
present and shown to act as decoy receptors in SLE patients,
with the result of blocking NF-κB signaling and subsequent B
cell survival, at least in vitro (Hoffmann et al., 2015; Laurent
et al., 2015). BAFF antagonists are investigated in the clinic to
prevent activation of B cell-driven mechanisms that contribute
to the pathology of autoimmune diseases. Belimumab (trade
name Benlysta) is a human monoclonal antibody against human
BAFF which has been approved for the treatment of lupus in
2011 (Hahn, 2013). Atacicept is a fully human recombinant
protein in which the ligand-binding portion of the extracellular
domain of TACI is fused to the Fc portion of a human IgG1
engineered not to bind Fc receptors and complement. Atacicept
significantly decreased circulating B cells and antibodies in
treated individuals and showed promising efficacy results in a
phase IIb clinical trial on patients with active, autoantibody-
positive SLE, under standard therapy (Merrill et al., 2018).
Belimumab and atacicept both inhibit membrane-bound and
soluble BAFF, but differ in their target specificity with regards
to APRIL, BAFF-APRIL heteromers and BAFF 60-mer which
are inhibited by atacicept but not by belimumab (Schuepbach-
Mallepell et al., 2015; Kowalczyk-Quintas et al., 2018). BAFF 60-
mer is an unusual form for a TNF family ligand in which twenty
3-mer are ordered in a pH-dependent capsid-like structure. It
was discovered in 2002, when recombinant BAFF was crystallized
alone or in complex with BAFFR or BCMA (Liu et al., 2002,
2003). Initial concerns that pH-dependent 60-mer formation
might be an artifact of the poly-histidine tag used for purification
(Zhukovsky et al., 2004) were wiped by the demonstration that
untagged BAFF produced in yeast also formed 60-mer, with pH
dependence being explained by the important role of a histidine
residue (H218; Cachero et al., 2006). H218 is located in a unique
loop of BAFF involved in BAFF-BAFF interactions and that
serves two functions. The first is to allow weak and transient 3-
mer to 3-mer interactions, that have no effect on receptor binding
but are essential to induce productive signaling through BAFFR,
probably by allowing interactions of BAFF-BAFFR complexes
once BAFF has bound to receptors. This function characterized
both in vitro and in vivo does not require 60-mer formation
as it is not affected by mutation H218A, but is destroyed by
the more “severe” E223K mutation in the flap (Vigolo et al.,
2018). The second function is the formation and stabilization of
BAFF 60-mer, in which each of the twenty BAFF 3-mer interacts
with 3 neighbors via flap-flap interactions crucially involving
His218 (Liu et al., 2002; Cachero et al., 2006; Vigolo et al., 2018).
Cross-linking of BAFF with antibodies that do not interfere
with receptor binding not only rescues the activity of “flap-
dead” BAFF mutants, but also stimulates the activity of wild
type BAFF (Kowalczyk-Quintas et al., 2016; Vigolo et al., 2018).
Transition of BAFF 60-mer to BAFF 3-mer at pH ≤ 7 is believed
to rely on protonation of His218. Atacicept can inhibit BAFF
60-mer, but belimumab cannot because its binding epitope in
BAFF 60-mer is inaccessible for steric hindrance reasons (Shin
et al., 2018; Vigolo et al., 2018). Given (a) the superior activity
Frontiers in Cell and Developmental Biology | www.frontiersin.org 2 November 2020 | Volume 8 | Article 577662
fcell-08-577662 November 3, 2020 Time: 14:20 # 3
Eslami et al. BAFF 60-mer and 60-mer-Dissociating Activities
of BAFF 60-mer over 3-mer (Liu et al., 2002, 2003), (b) its
potential to stimulate receptors that BAFF 3-mer cannot (Bossen
et al., 2008), (c) its differential susceptibility to clinical BAFF
antagonists (Shin et al., 2018; Vigolo et al., 2018), and (d) the
complete absence of data regarding its occurrence in humans, we
characterized BAFF in human serum and other biological fluids
making use of five criteria that are specific for BAFF 60-mer:
its size, its high activity, its pH-sensitivity, its refractoriness to
inhibition by belimumab and the inability to further activate its
activity with cross-linking anti-BAFF antibodies. In this study,
we distinguished three types of biological fluids: (i) human serum
that had no or very little detectable endogenous BAFF 60-mer.
On the contrary, a BAFF 60-mer inhibitory activity able to
dissociate spiked recombinant 60-mer into 3-mer was present in
adult human sera. Human lymph exudates behaved similarly. (ii)
cerebrospinal fluid (CSF) that contained neither BAFF 60-mer
nor BAFF 60-mer inhibitory activity and (iii) cord blood samples
that contained low levels of inhibitory activity but all displayed
a fair proportion of active, high molecular weight BAFF with
the size of BAFF 60-mer. Similar to BAFF 60-mer, the specific
activity of high molecular weight BAFF was higher than that
of BAFF 3-mer. Also, like BAFF 60-mer, high molecular weight
BAFF could dissociate into 3-mer. However, high molecular
weight BAFF was recognized and inhibited by antibodies unable
to bind undissociated recombinant BAFF 60-mer, suggesting
either that high molecular weight BAFF is not a 60-mer, or that
it is an easy-to-dissociate BAFF 60-mer. Regarding the BAFF
60-mer dissociating activity, it had a high molecular weight,
was resistant to protease inhibitors and to heating at 56◦C, did
not bind to immobilized BAFF but was inactivated by boiling.
We also describe that endogenous BAFF 3-mer does not re-
associate as 60-mer, even under favorable conditions after affinity
purification. Our data suggest two possible scenarios. In the first
one, BAFF 60-mer does not exist in vivo and high molecular
weight BAFF present in cord blood is part of an undefined
complex. In the second one, BAFF 60-mer can form locally but is
actively dissociated in adult human serum. It can persist in cord
blood, but in a more labile form than recombinant BAFF 60-mer.
MATERIALS AND METHODS
Human and Animal Samples
Normal adult human serum samples and cord blood samples
were as described (Podzus et al., 2017). Matched pairs of
serum and plasma were collected under the approval of the
Ethics Committee of the Medical University of Vienna, Austria
(EK Nr: 1845/2015). Human SLE serum samples were from
patients who were enrolled in the randomized, double-blind,
APRIL-SLE trial, but before they received any treatment with
atacicept (ClinicalTrials.gov Identifier NCT00624338). Serum
sample from a BAFFR-deficient person, of a Bruton’s tyrosine
kinase (BTK)-deficient patient and a CVID patient were as
previously described (Warnatz et al., 2009; Kreuzaler et al.,
2012). CSF samples from MS patients were provided by the
Institute of Clinical Neuroimmunology, Munich. This was
approved by the Ethical Committee of the Medical Faculty of
Ludwig-Maximilians-Universität München. Human lymphatic
exudate samples were collected from three melanoma patients
after sentinel lymph node surgery. Lymph was centrifuged
and stored at −20◦C until use (Broggi et al., 2019). For
cows, sera were from purebred German Fleckvieh, Vorderwald,
German Holstein cattle and from a Vorderwald by German
Holstein crossbred. All animal work was conducted according
to national and international guidelines for animal welfare. The
Lower Saxony state veterinary office at the Niedersächsisches
Landesamt für Verbraucherschutz und Lebensmittelsicherheit,
Oldenburg, Germany, was the responsible Institutional Animal
Care and Use Committee (IACUC) for this study. This
specific study had been approved by the IACUC of Lower
Saxony, the state veterinary office Niedersächsisches Landesamt
für Verbraucherschutz und Lebensmittelsicherheit, Oldenburg,
Germany (registration number 33.42502-05-04A247). Mouse
sera were obtained by puncture of the facial vein of C57Bl6
mice according to Swiss Federal Veterinary Office guidelines,
and under the authorization of the Office Vétérinaire Cantonal
du Canton de Vaud (authorization 1370.7 to PS). Blood was
incubated for 2 h at 37◦C, spun at 13,000 rpm for 15 min at 4◦C
and supernatant was collected.
Proteins and Antibodies
Belimumab (registered trade name Benlysta) and etanercept
(TNFR2-Fc, registered trade name Enbrel) were bought from
the Pharmacy of Lausanne University Hospital (CHUV). Rat
IgG2b anti-human BAFF monoclonal antibody 2.81 (Kreuzaler
et al., 2012) was from Adipogen (#AG-20B-0018-C100). Mouse
IgG anti-APRIL monoclonal antibody 104 was co-developed
with and provided by Adipogen. Its characterization will be
described in detail elsewhere. Mouse IgG1 anti-SHH 5E1 (Wang
et al., 2000) was purified from hybridoma supernatants obtained
from Developmental Studies Hybridoma Bank (University of
Iowa, Department of Biology, Iowa City, IA, United States).
Rat IgM anti-human BAFF monoclonal antibody Buffy2 was as
described (Schneider et al., 1999). Atacicept was provided by
Merck KGaA. Fc-BAFF and BCMA-Fc were stably transfected
and produced in CHO cells and affinity-purified on Protein
A-Sepharose as previously described (Schneider, 2000), or were
from Adipogen [Fc-BAFF, AG-40B-0120 and BCMA(h):Fc(h),
AG-40B-0080]. Fc-BAFF, atacicept, belimumab, mAb 104, and
mAb 5E1 were coupled at 2 (Fc-BAFF, 104, 5E1) or 5 mg/ml
(atacicept, belimumab, etanercept) to N-hydroxysuccinimide
(NHS)-Sepharose beads (GE Healthcare #90-1004-00) according
to manufacturer’s instructions. An expression plasmid for
Flag-BAFF was transiently transfected in 293T cells with the
polyethyleneimide method (Tom et al., 2008). 7 days later,
400 ml of conditioned supernatants in serum-free OptiMEM
medium were purified on a 1 ml column of atacicept-coupled
Sepharose, eluted with 50 mM citrate-NaOH pH 2.7, neutralized
with 1 M Tris–HCl pH 9, and buffer was exchanged for PBS
by ultrafiltration in a centrifugal device with 30 kDa cut off
(Amicon Ultra-4, Merck Millipore, #10210342). Flag BAFF forms
exclusively 3-mer. It was not further purified by size exclusion
chromatography (SEC). It was quantified by absorbance at
280 nm using an extinction coefficient of 16055 M−1 cm−1
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(absorbance at 1 mg/ml of 0.866). Naturally cleaved BAFF (wt,
H218A or E223K) in about 15 ml of conditioned cell supernatants
of transfected 293T cells was affinity purified on 12 µl of
atacicept-coupled Sepharose beads and size fractionated by SEC
in 20 mM Hepes, 130 mM NaCl, 10 µg/ml BSA, pH 8.2. Fractions
corresponding to BAFF 60-mer (8–10 ml) and BAFF 3-mer (14–
16 ml) were pooled, aliquoted and stored at −70◦C until use.
Naturally cleaved BAFF 60-mer and 3-mer were quantified by
BAFF ELISA with a capture step at pH 5.5 (see section “ELISA”).
3-mer fractions of BAFF mutants H218A and E223K were
quantified by Western blot using purified His-BAFF 60-mer as a
standard and mAb Buffy2 to reveal. His-BAFF 60-mer expressed
in Escherichia coli was from Adipogen (AG-40B-0112-C010). All
plasmids used in this study are listed in Supplementary Table 1.
Cell Lines
HEK 293T cells were obtained from late Jürg Tschopp (University
of Lausanne) and grown in DMEM 10% FCS. Jurkat JOM2
BAFFR:Fas-2308 cl21 and Jurkat BCMA:Fas-2309 clone 13
reporter cells were described previously and were grown in
RPMI 10% FCS (Bossen et al., 2008; Nys et al., 2013; Schneider
et al., 2014; Schuepbach-Mallepell et al., 2015). CHO-S cells
were from Thermoscientific (A1155701). CHO-S-2825 clone G5
expressing Fc-BAFF was obtained by transfection of CHO-S cells
by the polyethyleneimide method, selection by 3 passages in
500 µg/ml of G418 sulfate (Calbiochem, 345812) and cloning by
limiting dilution. The clone with highest production as assessed
by Western blot with horseradish peroxidase-coupled goat anti-
human Fc antibodies was selected for production.
Cytotoxic Assay
The activity of endogenous or recombinant BAFF was measured
using Jurkat BCMA:Fas-2309 clone 13 or Jurkat JOM2
BAFFR:Fas-2308 clone 21 reporter cells (Schneider et al.,
2014). In flat-bottomed 96 well cell culture plates, samples were
serially diluted as indicated into a final volume of 50 µl of RPMI,
10% FCS. Then, 50 µl of reporter cells (20’000–50’000/well)
in the same medium were added and incubated overnight
(∼16 h) at 37◦C, 5% CO2, after which time cell viability was
monitored by addition of 20 µl of PMS/MTS (phenazine
methosulphate at 45 µg/ml and 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium at
2 mg/ml in PBS) and measuring absorbance at 492 nm after 2–8 h
(Nys et al., 2013; Schneider et al., 2014; Schuepbach-Mallepell
et al., 2015). When tests were performed in the presence of
modifiers of BAFF activity (atacicept, belimumab, or anti-BAFF
2.81), modifiers at 10-fold the desired final concentration in
10 µl of RPMI 10% FCS were added, followed by reporter cells in
a volume of 40 µl instead of 50 µl. When tests were performed
to measure the inhibitory activity of serum or other biological
fluids on recombinant BAFF 60-mer, 2 µl of sera or fluid were
added per well, unless stated otherwise. In some instances,
serum was heated for 30 min at 56◦C. In other instances,
size exclusion chromatography fractions of normal human
serum were heated for 5 min at 95◦C, then spun for 15 min
at 13,000 rpm in a tabletop centrifuge to remove precipitated
proteins, and supernatant were used in the assay. Where
indicated, one-fold concentrated protease inhibitor cocktail
(Sigma, “cØmplete,” 11697498001) was added to serum prior to
the assay. Reporter cells were not affected by this concentration
of protease inhibitors in the time frame of the assay. Optionally,
antibiotics (Invitrogen, 15070–063) were added in samples or
cells to have a final concentration of 50 U/ml streptomycin and
50 µg/ml penicillin, in particular when non-sterile samples were
tested, such as size exclusion chromatography fractions. For the
estimation of the percentage of high molecular weight BAFF
at the activity level after size exclusion chromatography, EC50
expressed in µl of fraction was first determined for fractions 9,
14, and 15, then the following calculation was performed: % high
molecular weight BAFF activity = [(1/EC50 of fraction 9)/(sum of
(1/EC50) of fractions 9, 14, and 15)] × 100.
BAFF ELISA
Endogenous or recombinant human BAFF was quantified using
BAFF (human) ELISA kit from Adipogen (#AG-45B-0001-KI01)
according to the manufacturer’s protocol, using 2.5 µl or 10 µl
of human sera as indicated, or 3 µl of serum from cord blood,
or 100 µl of human CSF samples. For SEC fractions, adjusted
volumes were used for the BAFF ELISA (Supplementary
Table 2). The capture step was performed in ELISA buffer
provided with the kit (pH 7.4). When indicated, for the detection
of BAFF 60-mer, the capture step was performed for 3 h
at room temperature in MES [2-(N-morpholino)ethanesulfonic
acid] buffer pH 5.5. For this purpose, suitable amounts of 0.5 M
MES pH 5 were added to samples prior to the capture step of the
ELISA. This amount was determined for each type of buffer by
controlling pH on a pH paper with a 0.5 pH unit scale. For the
measurement of endogenous BAFF in 200 µl cord blood right
after size exclusion chromatography, 150 µl of 1 ml fractions were
immediately captured for 30 min at 4◦C and pH 7.4 or pH 5.5. For
the estimation of the percentage of high molecular weight BAFF
at the protein level, the following calculation was performed: %
high molecular weight BAFF protein = [signal in fraction 9/(sum
of signals in fractions 9, 14, and 15)] × 100.
Size-Exclusion Chromatography
A dedicated Superdex S200 Increase HR 10/30 columns was
used for the analysis of samples containing endogenous BAFF,
and another for samples containing recombinant BAFF. This
can explain small differences in the retention time of standards.
Size-exclusion chromatography with 200 to 400 µl of samples
was performed at a flow rate of 0.65 ml/min in 20 mM Hepes,
130 mM NaCl, pH 8.2. For diluted samples in the absence of
a protein matrix, 10 µg/ml bovine serum albumin was added
in the buffer. For samples with low endogenous BAFF levels
requiring subsequent lyophilization, 10 mM Hepes, 30 mM NaCl,
10 µg/ml BSA, pH 8.2 was used. Fractions of 1 ml were collected.
Lyophilized fractions were suspended into 100 or 200 µl of water
to get 10-fold or 5-fold concentrated fractions, including salts and
buffer. When indicated, pooled fractions were concentrated using
30 kDa cut off centrifugal concentration devices to a volume
of about 300 µl prior to re-injection. Columns were calibrated
with 100 µl of a mixture of protein standards, all at 1.4 mg/ml
(except ferritin at 140 µg/ml): thyroglobulin (669 kDa), ferritin
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(440 kDa), aldolase (158 kDa), ribonuclease A (13.7 kDa; all from
GE Healthcare), bovine serum albumin (67 kDa), ovalbumin
(43 kDa), carbonic anhydrase (29 kDa), and aprotinin (6.5 kDa;
all from Sigma-Aldrich).
Immunoprecipitation
To purify or deplete endogenous or recombinant BAFF from
human serum, CSF or other samples, samples were mixed with
20 µl of a 50% slurry in PBS of NHS-Sepharose beads coupled
to the desired protein or antibody, and incubated overnight at
4◦C on a rotating wheel. Beads were centrifuged for 5 min at
5,000 rpm (2,400 × g). The unbound fraction was collected,
while beads were washed 3 times with 100 µl of PBS in mini
columns (Schneider et al., 2014) and eluted with 30 µl of 50 mM
citrate-NaOH pH 2.7. The eluate was neutralized with 10 µl of
1 M Tris–HCl pH 9.
Western Blot
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) of 12% acrylamide gels and Western blot on nitrocellulose
membranes were performed according to standard protocols.
His-BAFF-60mer at 50, 25, 12.5, and 6.25 ng per lane was used
as a standard. Membrane were revealed with Buffy2 at 1 µg/ml,
followed by horse radish peroxidase-coupled goat anti-rat IgM, µ
chain specific (Jackson ImmunoResearch, 112-035-075) at 1/8000
and ECL. Concentrations of naturally cleaved BAFF H218A and
E223K were estimated by comparing band intensities. The same
Western blot procedure was used to reveal naturally cleaved
BAFF in fractions of size exclusion chromatographies.
Statistics
Statistics were performed with Prism 8 (GraphPad Software).
Normal distribution of data was assessed with D’Agostino
Pearson normality test for n ≥ 8, or assumed to be so for
n < 8. Standard deviations were not assumed to be equal
and comparisons of multiple groups was performed by Brown-
Forsythe and Welch ANOVA test, followed by Dunnett T3
multiple comparison tests. For the comparison of 2 groups, t-test
with Welch’s correction was used. Differences were considered
significant when P < 0.05. To determine the EC50 of titration
curves, cell viability was first normalized, then fitted with the
“Non-linear regression (curve fit)” followed by the “log(agonist)
vs. normalized response-variable slope” functions of Prism 8
(GraphPad Software).
RESULTS
Elevated BAFF in BAFFR-Deficient
Human Serum Is Exclusively in a Trimeric
Form
Serum samples collected at different times from a BAFFR-
deficient individual displayed BAFF levels by ELISA that were
on average 500-fold higher than those of controls and 50-
fold higher than those of SLE patients (Figure 1A). BAFF in
BAFFR-deficient serum, but not normal serum, was detectable
in a cell-based activity assay, in which target cells are Jurkat T
cells expressing the chimeric receptor BCMA:Fas (Figure 1B).
These cells divert BAFF (and APRIL) signals into death via
the intracellular domain of the apoptosis-inducing receptor Fas.
Endogenous BAFF and APRIL in normal human serum were
under the detection limit (Figure 1B). As APRIL levels are not
elevated in BAFFR-deficient serum (unpublished observation),
APRIL likely did not contribute to signal in this experiment, as
will be confirmed later with BAFF-specific reporter cells. The
human BAFFR-deficient serum was thus used to investigate the
ratio of activity associated with BAFF 3-mer and BAFF oligomers
after a size-fractionation performed at pH 8.2, a pH that is
favorable to BAFF 60-mer (Cachero et al., 2006). BAFF activity
was recovered in late fractions (15–17). No activity was detected
in early fractions (9 and 10) that would correspond to BAFF 60-
mer (Figures 1C,D). To test the hypothesis that BAFF assembly
into 60-mer at pH 8.2 might be a slow process, fractions 15–
17 were pooled, concentrated and size-fractionated again at pH
8.2, but BAFF activity still eluted in late fractions (Figure 1E).
The theoretical molecular weight of naturally processed BAFF
is 51 kDa (3 × 17 kDa), and calibration markers indicated an
apparent size of 46 kDa for endogenous BAFF activity (2.7-mer).
Under identical conditions, a recombinant His-BAFF that was
undoubtedly trimeric by electron microscopy and crystallization
also eluted as an apparent 2.7-mer relative to molecular weight
markers (Vigolo et al., 2018). Taken together, these results
indicate that endogenous BAFF in BAFFR-deficient serum is
present as 3-mer, and that the absence of 60-mer is not a
consequence of a potentially inadequate pH of serum.
Human Serum Contains a High
Molecular Weight Inhibitory Activity for
BAFF 60-mer
We wondered whether BAFF 60-mer activity would have been
detected if present in serum. Thus, the activity of recombinant
His-BAFF 60-mer (Vigolo et al., 2018) spiked into normal human
serum was measured, but this time on BAFFR:Fas reporter cells
that are more sensitive to BAFF and, unlike BCMA:Fas reporter
cells, cannot respond to APRIL. The activity of BAFF 60-mer
was decreased by up to two orders of magnitude when it was
spiked into normal human serum compared to 60-mer spiked
into fetal calf serum (Figure 2A). This could have been due to
the presence of shed soluble BAFFR, TACI, and/or BCMA, all
of which have been described (Hoffmann et al., 2015; Laurent
et al., 2015; Smulski et al., 2017), but pre-depletion of serum
on beads coupled to recombinant Fc-BAFF, which could remove
soluble TACI, BAFFR, and BCMA (Supplementary Figure 1),
did not alter the inhibitory activity (Figure 2A). After serum
concentration using an ultrafiltration device with 30 kDa cut
off, and exchange of the serum matrix for PBS, all 60-mer
inhibitory activity was recovered and enriched in the retained
fraction, and none passed into the low molecular weight fraction
(Figure 2B). In line with these results, the inhibitory activity
recovered after size-exclusion chromatography was in the high-
molecular weight fractions, and not in smaller molecular weight
Ig- or albumin-containing fractions (Figures 2C,D). It was
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FIGURE 1 | Endogenous BAFF activity in serum of a BAFFR-deficient person has the size of a 3-mer. (A) Concentrations of endogenous BAFF measured by ELISA
in 2.5 µl of normal human sera, in sera of SLE patients and in three independent serum samples of a BAFFR-deficient person. * indicates significant (P < 0.001)
difference with the control group of normal human sera by one-way ANOVA with Bonferroni’s multiple comparison test. One experiment out of three with comparable
results is shown. (B) The activity of endogenous BAFF in the indicated volume of BAFFR-deficient and normal human serum, or in foetal calf serum (FCS), or in
culture medium (10% FCS) was monitored with BCMA:Fas reporter cells. The final assay volume was 100 µl. Cell viability was measured with the PMS/MTS assay.
This experiment was performed twice in this format, and three more times on similar reporter cells (BAFFR:Fas). (C) A mixture of molecular weight markers (top
panel) was fractionated by SEC in Hepes buffer pH 8.2, and detected by on-line monitoring of absorbance at 280 nm. (D) a BAFFR-deficient human serum was
fractionated by SEC in Hepes buffer pH 8.2. Fractions were concentrated 3-fold by ultrafiltration and BAFF activity in each fraction was monitored by its ability to kill
BCMA:Fas reporter cells. The experiment was performed three times (plus once with a different readout). (E) Fractions 15–17 of the chromatography shown in panel
(D) were pooled, concentrated by ultrafiltration, fractionated again by SEC, and analyzed for BAFF activity as shown in panel (D). This experiment was performed
once.
abolished by heating at 95◦C (Figure 2E), but resisted heating
at 56◦C (Supplementary Figure 2A) and was unaffected by a
cocktail of protease inhibitors (Supplementary Figure 2B). The
inhibitory activity was consistently found in adult human sera
and plasma (Supplementary Figure 2C), and in sera of adult
cows (Figure 2F). It was present in varying amounts in sera
obtained from human cord blood, but usually lower than in
adult sera (Figure 2G). It was particularly low in two cord blood
samples of pre-term babies born at gestational weeks 28 or 29
(Figure 2H). It was not present in fetal calf serum and adult
mouse sera (Figure 2I).
A BAFF ELISA Recognizes BAFF 60-mer
Only When BAFF Is Captured at pH 5.5
Purified recombinant Flag-BAFF was eluted by size-exclusion
chromatography at a size of 67 kDa, slightly higher than its
theoretical size of 56 kDa (3.6-mer). It was recognized in the
BAFF ELISA at both pH 7.4 and pH 5.5 (Figures 3A,B). In
contrast, His-BAFF 60-mer, and the 60-mer fraction of naturally
processed full-length BAFF in supernatants of transfected 293T
cells, were not recognized at pH 7.4 and only detected at pH
5.5 (Figures 3C–E). This probably indicates that a concealed
epitope in BAFF 60-mer becomes available for capture upon acid-
dissociation. Thus, the capture of BAFF at pH 5.5 is mandatory to
detect BAFF 60-mer.
The BAFF 60-mer Inhibitory Activity of
Human Serum Dissociates BAFF 60-mer
Into 3-mer and Is Saturable
BAFF 60-mer spiked into Hepes buffer at pH 8.2 or in human
serum was size-fractionated by size-exclusion chromatography
and detected in fractions by ELISA at pH 5.5 and by its
activity on BAFFR:Fas reporter cells. In Hepes buffer, both
protein and activity eluted in high molecular weight fractions,
as expected for BAFF 60-mer (Figures 4A,B), but when spiked
into serum, BAFF 60-mer protein was recovered at the size
of BAFF 3-mer, while the leftover activity was still mainly 60-
mer and partially 3-mer, suggesting that highly active 60-mer
was almost entirely dissociated to less active 3-mer by exposure
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FIGURE 2 | Human serum contains a BAFF 60-mer inhibitory activity. (A) Recombinant His-BAFF 60-mer was titrated on BAFFR:Fas reporter cells in the presence
of a constant amount of FCS (10%), or of normal human serum, or of normal human serum depleted on Fc-BAFF-coupled Sepharose beads. After an overnight
incubation, cell viability was monitored. The experiment was performed three times. (B) Normal human serum was concentrated 2-fold by ultrafiltration, then washed
with PBS by ultrafiltration. FCS, normal serum, 2-fold concentrated normal serum before and after wash with PBS, and the filtrated fraction of normal serum were
tested on BAFFR:Fas reporter cells as described in panel (A). The experiment was performed four times. (C) 400 µl of normal serum was size-fractionated by SEC.
The indicated fractions were pooled, concentrated to 400 µl, and 1 µl was analyzed by SDS-PAGE and Coomassie blue staining under reducing (+DTT) or
non-reducing conditions (-DTT). This experiment was performed twice. (D) Serum fractions as shown in panel (C) were analyzed for their BAFF 60-mer inhibitory
activity as described in panel (A). The experiment was performed four times. (E) Same as panel (D), except that supernatants of fractions heated for 5 min at 95◦C
were analyzed. The result with medium only is the same as in panel (D). (F–I) four adult cow sera (F), 7 sera from human cord blood (G), two sera from cord blood of
pre-term babies at gestational weeks 28 and 29 (H) and 4 adult mouse sera (I) were analyzed with the indicated controls as described in panel (A). In panel (G), 3*
and 5* indicate that cord sera 3 and 5 contained an intrinsic BAFF activity that killed about 50% of reporter cells in the absence of BAFF 60-mer. Experiment (E) was
performed once. Experiments (F), (G), and (I) were performed three times each, and experiment (H) was performed twice.
to human serum (Figures 4C,D). If serum inhibits BAFF 60-
mer by dissociation, then non-dissociable BAFF oligomers such
as hexameric Fc-BAFF should be unaffected by serum. Indeed,
human serum inhibited BAFF 60-mer in a concentration-
dependent manner (Figure 5A), but did not affect the activity
of Fc-BAFF (Figure 5B). To demonstrate whether the BAFF 60-
mer inhibitory activity was saturable, increasing concentrations
of BAFF 60-mer were spiked into a fixed volume of human serum,
and then size fractionated. BAFF was then detected by ELISA at
pH 5.5 in adequately diluted fractions, and the percentage of total
BAFF in each fraction was calculated. BAFF 60-mer spiked into
buffer at pH 8.2 eluted as 60-mer (Figure 5C). When 60-mer was
spiked at 100 ng/ml in human serum, almost all of it dissociated
to BAFF 3-mer. At 7 µg/ml, only about half dissociated into 3-
mer, whereas at 500 µg/ml, almost all of it remained 60-mer
(Figure 5D). We take these results as a strong indication that
although the BAFF 60-mer-dissociating activity in human serum
is limited and saturable, it is very high (EC50 of about 7 µg/ml)
compared to usual circulating BAFF levels.
Recombinant BAFF 60-mer Activity
Resists Affinity Purification but Is
Irreversibly Attenuated in Normal Human
Serum
To test whether attenuation of BAFF 60-mer activity in human
serum is a reversible process, the activity of BAFF 60-mer spiked
into different matrices was analyzed before and after affinity
purification procedures on immobilized TACI-Fc (atacicept) or
belimumab. BAFF 60-mer bound efficiently to atacicept but
not to belimumab. About 10% of atacicept-bound BAFF 60-
mer activity was recovered after acid elution, neutralization, and
buffer exchange to Hepes pH 8.2 (Supplementary Figure 3).
However, when BAFF 60-mer was spiked into human serum,
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FIGURE 3 | A human BAFF ELISA detects BAFF 60-mer at pH 5.5 but not at pH 7.4. (A) 50 µg of Flag BAFF 3-mer was fractionated by SEC at pH 8.2 and
detected by on-line UV monitoring (thin line). Fractions were tested by BAFF ELISA with the capture step performed at pH 7.4 (white circles) or pH 5.5 (black circles).
(B) Titration of Flag-BAFF 3-mer from SEC fractions 14 + 15 measured by BAFF ELISA with capture at pH 7.4 (white squares) or pH 5.5 (black squares). LLD: lowest
limit of detection. (C,D) Same as panels (A,B), but with 100 µg of His-BAFF 60-mer and His-BAFF 60-mer from SEC fractions 9 + 10. Experiments of panels (A–D)
were performed once in this format, but pH sensitive detection of BAFF 60-mer was confirmed in 3 more experiments in different formats. (E) Same as panels (A),
but with naturally cleaved BAFF in concentrated supernatants of 293T cells transfected with full length human BAFF, and with 10 µg/ml BSA in buffer. The
experiment was performed twice.
very little activity was recovered after affinity purification on
atacicept and buffer exchange to Hepes pH 8.2, suggesting that
serum inhibition of BAFF 60-mer is irreversible and cannot
be reversed by removing serum and reverting back to 60-mer-
friendly conditions (Supplementary Figure 3).
Human Cerebrospinal Fluid Contains
BAFF but no BAFF 60-mer Inhibitory
Activity
Owing to its inhibitory activity, human serum might not be
the right place to detect BAFF 60-mer. Human lymph exudate
also inhibited BAFF 60-mer activity (Figure 6A), although
we cannot exclude that this could be due to contaminating
serum. In contrast, CSF of three patients with MS did not
inhibit BAFF 60-mer activity, while their corresponding sera
did (Figures 6B,C). The absence of BAFF-inhibitory activity
was confirmed in four more CSF samples (Figure 6D) that
all contained low but detectable levels of endogenous BAFF
(Figure 6E). After concentration of pooled CSF samples, an
atacicept inhibitable BAFF activity was indeed detectable using
BAFFR:Fas reporter cells (Figure 6F), raising the possibility that
BAFF 60-mer may exist in CSF.
BAFF in Human Cerebrospinal Fluid
Forms 3-mer
Pooled CSF samples were concentrated, fractionated by size
exclusion chromatography at pH 8.2 and assayed for BAFF
content by ELISA at pH 5.5 and on BAFFR:Fas reporter cells.
Both assays exclusively detected BAFF at the size of a 3-mer,
while a positive control of BAFF 60-mer analyzed under the
same conditions eluted with the expected high molecular weight
(Figures 7A–D). We hypothesized that a portion of BAFF
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FIGURE 4 | Human serum dissociates His-BAFF 60-mer into less active 3-mer. (A) 40 ng of His-BAFF 60-mer in Hepes pH 8.2, 50 µg/ml BSA was size fractionated
by SEC and the presence of BAFF in 70 µl of fractions was analyzed by BAFF ELISA with capture at pH 5.5. (B) The indicated volumes of the same factions as in
panel (A) were analyzed for their activity on BAFFR:Fas reporter cells. (C,D) Same as panels (A,B), except that the same amount of BAFF 60-mer was spiked into
400 µl of normal human serum at pH ∼8 prior to fractionation by SEC at pH 8.2. The experiments of panels (A,C) were performed 3 times, and those of panels
(B,D) twice.
FIGURE 5 | BAFF 60-mer dissociation activity of human serum is saturable. (A) The inhibitory activity of normal human serum mixed with FCS at the indicated ratio
on His-BAFF 60-mer was tested on BAFFR:Fas reporter cells. (B) Same as panel (A), but using Fc-BAFF instead of His-BAFF 60-mer. The experiments of panels
(A,B) were performed three times. (C) His-BAFF 60-mer spiked at 0.1 (white circles), 7 (gray circles), or 500 µg/ml (black circles) in 400 µl of Hepes buffer at pH 8.2
was size-fractionated by SEC at pH 8.2 and analyzed in adequately diluted fractions by BAFF ELISA with capture at pH 5.5. Data is normalized to the total signal in
fractions 7 to 18 for each individual run. (D) Same as panel (C), except that His-BAFF 60-mer was spiked into 400 µl of normal human serum. The experiment of
panels (C,D) was performed twice.
in CSF could be engaged into BAFF-APRIL heteromers that
would inhibit 60-mer formation, but after passage of CSF on
an immobilized anti-APRIL antibody able to deplete BAFF-
APRIL heteromers, BAFF was still present as 3-mer in CSF
(Figures 7E,F). When endogenous BAFF present in CSF or in a
BAFF-high serum sample (from a patient with common variable
immunodeficiency) was affinity-purified on atacicept prior to
size-fractionation at pH 8.2, only BAFF 3-mer was detected,
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FIGURE 6 | Human cerebrospinal fluid contains BAFF protein and activity, but no BAFF 60-mer inhibitory activity. (A–D) Three human samples of lymph exudate (A),
3 human CSF samples of multiple sclerosis patients (B), 3 human sera of patients corresponding to CSF samples of panel (B,C) and 4 additional CSF samples from
multiple sclerosis patients (D) were tested for their inhibitory activity on His-BAFF 60-mer using BAFFR:Fas reporter cells. Experiments in panels (A–C) were
performed 3 times and that of panel (D) once. (E) BAFF levels measured by BAFF ELISA with capture at pH 7.4 in the 4 CSF samples of panel (D). This experiment
was performed once in this format. Detection of BAFF by ELISA in CSF sample was performed 4 times in different formats in these or other CSF samples. (F) A pool
of CSF samples from panels (D,E) was concentrated 8-fold by ultrafiltration with cut off at 30 kDa. BAFF activity of concentrated CSF (CSF conc), of the filtered
fraction of CSF (CSF FT) and of buffer was monitored on BAFFR:Fas reporter cells in the presence or absence of atacicept at 100 ng/ml. The experiment was
performed once in this format. Detection of BAFF activity in these or other CSF samples was performed five times in different formats (including in Figure 7).
indicating the BAFF in CSF and in CVID serum is not only 3-mer,
but also unable to associate as 60-mer under favorable conditions
(Figures 7G,H).
A High Molecular Weight Form of BAFF
in Cord Blood
Because fetal calf serum contains less BAFF 60-mer dissociating
activity than adult cow serum, we tested whether human
cord blood that also contains low dissociating activity may
contain BAFF 60-mer. BAFF in fractions of the size exclusion
chromatography was monitored by activity using BAFFR:Fas
reporter cells, and by ELISA. As BAFFR:Fas reporter cells
are highly sensitive to BAFF oligomers (Vigolo et al., 2018),
but less so to BAFF 3-mer, they cannot detect low levels
of endogenous BAFF 3-mer. Activity assays were therefore
systematically performed in the presence of the cross-linking
anti-human BAFF mAb 2.81, that we found was able to enhance
the activity of BAFF 3-mer (see later). Also, the BAFF ELISA
was systematically performed at pH 5.5 in order to detect both
3-mers and 60-mers. This also allows to compare total BAFF
protein to activity. Finally, because the chromatography system
was also used by our laboratory to purify recombinant BAFF
60-mer or TACI-Fc, the entire system was thoroughly cleaned
until no trace of BAFF activity, or BAFF inhibitory activity was
detected (Figure 8A). BAFF in normal adult sera was detected
as 3-mer, with only traces of higher molecular weight BAFF, and
we confirmed that this was also the case for CVID and BAFFR-
deficient sera (Figures 8B–F). However, all cord blood sera,
including one of a pre-term child at gestational week 29 contained
fair proportions of high molecular weight BAFF in addition to
3-mers: up to 13% by ELISA and up to 40% in the activity test
(Figures 8G–N). A single child serum was analyzed. It resembled
adult serum more than cord serum (Figure 8O). An adult serum
from a patient without B cells (BTK deficiency) contained 3-
mer only, suggesting that differences observed for high molecular
weight BAFF between cord blood and adults was not B cell-
related (Figure 8P). In cord sera, despite the presence of the
activating antibody, high molecular weight BAFF consistently
displayed a higher specific activity compared to BAFF 3-mer,
which is one of the characteristics of BAFF 60-mer. We excluded
that formation of high molecular weight BAFF would be induced
only in Hepes pH8.2, because it was also observed when the
column was equilibrated in 25% fetal calf serum instead of Hepes
buffer pH 8.2 (Figure 8Q). A direct measure in twelve cord blood
samples revealed BAFF levels that were on average13-fold higher
than in healthy adult sera (Figure 8R).
High Molecular Weight BAFF in Cord
Blood Can Dissociate Into 3-mers
Size exclusion chromatography fractions of one of the cord
blood samples were monitored for BAFF activity with or without
activating antibody. As expected, the activity of BAFF 3-mer
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FIGURE 7 | BAFF protein and activity in human CSF has the size of a 3-mer, even after depletion of BAFF-APRIL heteromers or after affinity-purification.
(A) His-BAFF 60-mer in Hepes buffer at pH 8.2 was fractionated by SEC at pH 8.2 in a buffer with 140 mM NaCl and no BSA. Small aliquots diluted in the same
buffer with 30 mM NaCl were lyophilized, dissolved in a tenth of the volume and measured by BAFF ELISA with capture at pH 5.5. The experiment was performed
once in this format, and three times in different formats. (B) Fractions of panel (A) were analyzed for BAFF activity on BAFFR:Fas reporter cells. This experiment was
performed twice. (C) Same as panel (A), except that 200 µl of an 8-fold concentrated pool of CSF from patients with multiple sclerosis (4–7 in Figures 6D,E) was
analyzed instead of His-BAFF 60-mer, and that Hepes buffer contained 30 mM NaCl only, and that fractions were lyophilized and dissolved in a fifth of the initial
volume prior to analysis. (D) Fractions of panel (C) were analyzed for BAFF activity on BAFFR:Fas reporter cells. Experiments of panels (C,D) were performed once
in this format, and three times in different formats (panels E–H). (E) CSF depleted on mAb 104, which removes APRIL and BAFF-APRIL heteromers, was
size-fractionated at pH 8.2 in the presence of Hepes buffer containing 30 mM NaCl and 10 µg/ml BSA. After lyophilization of fractions and suspension in a tenth of
the original volume, BAFF was detected by ELISA with capture at pH 5.5 (black circles). Mock-depleted CSF was also analyzed (white circles). (F) Fractions of panel
(E) were analyzed for BAFF activity on BAFFR:Fas reporter cells. (G) BAFF affinity-purified on atacicept from patients with multiple sclerosis (4–7 in Figures 6D,E;
white circles), or serum from a CVID patient (black circles) were size fractionated by SEC at pH 8.2. BAFF in fractions was detected by ELISA with capture at pH 5.5.
Note that the Y-axis scale is different for both samples. (H) Fractions of panel (G) were tested for BAFF activity on BAFFR:Fas reporter cells. A 4-fold higher fraction
volume was used to measure BAFF activity in CSF compared to CVID. Experiments of panels (E,G) were performed once. Measures in panel (F) were performed
twice, from the same fractions. Measures in panels (F,H) were performed at 3 different dilutions, one of which is shown.
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FIGURE 8 | Consistent detection of a high molecular weight form of BAFF in cord blood. Human sera were fractionated by SEC in Hepes pH 8.2, 30 mM NaCl,
10 µg/ml BSA. Fractions were lyophilized, redissolved in one tenth of the volume, and used to monitor BAFF activity on BAFFR:Fas reporter cells in the presence of
the activating anti-BAFF antibody 2.81. Fractions were also measured for BAFF content by ELISA with a capture step at pH 5.5. (A) Negative control with buffer only.
(B–D) Normal human adult sera. (E) Serum from a CVID patient. (F) Serum from a BAFFR-deficient individual. (G) Serum from cord blood of a pre-term baby at
gestational week 29. (H–N) Cord blood sera. Note that serum in panel (H) was analyzed before in-depth cleaning of the chromatography system and may contain
traces of TACI-Fc. Peak 3-mer fractions in panel (M) were measured at 3 different dilutions, showing a linear relationship between signal and dilution. (O) Serum from
a 7 year-old child. (P) Serum from a BTK-deficient patient. (Q) Pooled cord blood sera #5 and #7 size fractionated in a column equilibrated in 25% fetal calf serum
instead of Hepes buffer pH8.2 (R) Concentrations of BAFF were measured by ELISA at pH 7.4 in 10 µl of normal human sera (n = 11) and in 3 µl of sera of cord
blood (n = 12), using Flag-BAFF as a standard. Groups were compared by t-test with Welch’s correction. *p < 0.05.
was enhanced with the activating antibody, but high molecular
weight BAFF was activated too (Figure 9A), suggesting it might
have dissociated into 3-mers. When the high molecular weight
BAFF fraction was fractionated again, about 60% had dissociated
into 3-mers while the remaining was still big (Figure 9B). On
the contrary, the trimeric fraction did not detectably re-associate
into multimers (Figure 9C). Naturally processed full-length
recombinant BAFF yielded BAFF 3-mer and 60-mer in roughly
similar quantities, as detected by Western blot (Figure 9D).
Unexpectedly, the activity of the 60-mer on reporter cells was
similar to that of BAFF 3-mer in terms of signal and of response
to ligand (Figure 9D), which could be attributed at least in part to
an equilibrium between 60-mer and 3-mer after size separation.
Re-fractionation of BAFF 60-mer indeed yielded again 3-mer
and 60-mer in equivalent amounts (Figure 9E), while the 3-mer
remained essentially 3-mer, with moderate amounts of 60-mer
detected by the activity test, but not by Western blot (Figure 9F).
Taken together, these results show that high molecular weight
BAFF in cord blood can dissociate into 3-mers similarly to
naturally cleaved BAFF 60-mer.
Epitopes Concealed in Recombinant
BAFF 60-mer Are Accessible in High
Molecular Weight BAFF From Cord Blood
B cell activating factor 60-mer forms a defined, organized
structure, with receptor-binding site always exposed at the
surface, while other surfaces are always pointing inside of the 60-
mer, or are buried in 3-mer to 3-mer interactions (Liu et al., 2002,
2003). Thus, antibodies against BAFF 3-mers do not necessarily
recognize BAFF 60-mer. Belimumab is a well characterized
example of an antibody that cannot recognize BAFF 60-mer (Shin
et al., 2018; Vigolo et al., 2018). Our results also suggest that
the capture antibody of the BAFF ELISA does not recognize
BAFF 60-mer at pH 7.4, unless BAFF is first (presumably)
dissociated into 3-mer at pH 5.5 (Figures 3C,D). We tested
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FIGURE 9 | High molecular weight cord blood BAFF and naturally cleaved BAFF 60-mer similarly dissociate into 3-mer. (A) Cord serum was analyzed as described
in Figure 8, but in the absence (top panel) or presence (bottom panel) of activating anti-BAFF 2.81 antibody. (B) Fractions 8–10 of panel (A) were concentrated and
re-fractionated by SEC. Lyophilized fractions were analyzed on BAFFR:Fas reporter cells without or with activating anti-BAFF 2.81 antibody. (C) Same as panel (B),
but with fractions 14–17 from panel (A). (D) Conditioned supernatants of 293T cells transiently transfected with full-length human BAFF were size-fractionated by
SEC in PBS pH 7.4. Fractions were analyzed by anti-BAFF (Buffy-2) western blot (top panel), or by activity on BAFFR:Fas reporter cells without (middle panel) or with
2.81 (bottom panel). (E) Fractions 9–10 of panel (D) were concentrated by affinity-purification on atacicept and analyzed again by SEC in Hepes at pH 8.2, Western
blot and activity tests. (F) Same as panel (E), but with affinity-purified fractions 14–17 of panel (D). Note that affinity-purification steps render results of panels (E,F)
not directly comparable with those of panels (B,C).
whether high molecular weight BAFF in cord sera would escape
recognition by antibodies specific for BAFF 3-mer. Thus, a
serum of cord blood was analyzed in parallel with a standard of
naturally cleaved BAFF 60-mer added in the same matrix. For this
purpose, cord-blood was first depleted from endogenous BAFF
with immobilized TACI-Fc, then supplemented with a close-to-
endogenous concentration of recombinant 60-mer purified from
naturally cleaved BAFF. These samples were size-fractionated
by SEC. Fractions were immediately added to ELISA plates at
4◦C so that the capture step was completed in less than an
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hour post-elution. High molecular weight BAFF and BAFF 3-
mer in cord blood were detected in the BAFF ELISA at both
pH, suggesting it does not contain BAFF 60-mer (Figure 10A).
Recombinant 60-mer spiked into the same matrix eluted as 60-
mer and 3-mer. As expected, 60-mer was detected at pH 5.5,
but poorly at pH 7.4, while the 3-mer was detected at both pH
(Figure 10B). This suggests that high molecular weight BAFF
in cord blood is different from naturally cleaved, recombinant
BAFF 60-mer. Further controls indicated that BAFF 3-mer in
purified naturally cleaved BAFF 60-mer was already present
before spiking the depleted serum. Indeed, the ELISA recognized
this standard at pH 5.5, as expected, but also to a fair extent at
pH 7.4, while the more stable His-BAFF 60-mer was recognized
at pH 5.5, but not or only weakly at pH 7.4 (Figures 10C,D).
We next tested whether high molecular weight BAFF in cord
blood would be resistant to belimumab, as would be expected for
BAFF 60-mer, using BAFFR:Fas reporter cells. The development
and the characteristics of this assay are described in detail
in the Supplementary Material (Supplementary Figures 4–7).
Briefly, BAFF-containing samples were titrated on reporter cells,
in a medium at pH 8.2 to favor 60-mers, in four different
conditions: (i) without modifiers, (ii) with anti-BAFF antibody
2.81 that activates BAFF 3-mer by cross-linking but has no
effect on BAFF 60-mer, (iii) with atacicept that inhibits all
forms of BAFF, and (iv) with belimumab that inhibits BAFF
3-mer, but minimally affects BAFF 60-mer. This test permits
the detection of recombinant His-BAFF 60-mer in the pg/ml
range, even in the presence of an excess of Flag-BAFF 3-mer
(Supplementary Figure 5). Thus, Flag-BAFF that exclusively
forms 3-mer (Schneider et al., 1999), is activated about 10-fold
by 2.81, but inhibited by belimumab and atacicept (Figure 11A).
Similar results were observed for the 3-mer fraction of naturally
cleaved WT BAFF, or of naturally cleaved BAFF with the H218A
mutation that prevents 60-mer formation (Vigolo et al., 2018;
Figures 11B,C). With the more “severe” mutation E223K that
abolishes signaling ability, but not receptor binding (Vigolo et al.,
2018), naturally cleaved BAFF was fully dependent on the cross-
linking action of 2.81 (Figure 10D). In contrast, recombinant
His-BAFF 60-mer was active on its own, was not further activated
by 2.81, was fully resistant to inhibition by belimumab, but
sensitive to inhibition by atacicept (Figure 11E). Similar results
were obtained with the 60-mer fraction of naturally cleaved
WT BAFF, except that the activity was overall lower, and that
it was weakly inhibited by belimumab, as anticipated if a fair
proportion of less active 3-mer would be inhibited in this
preparation (Figures 11F,G). Cord blood samples consistently
behaved as standards of BAFF 3-mer in this assay, and there
was no difference between inhibitions by belimumab or atacicept
(Figures 11H–L). Given the proportion of high molecular weight
BAFF observed after SEC (Figure 8), if this high molecular
weight BAFF would have had the activity of His-BAFF 60-mer, it
should have been detected in this assay. We conclude that under
conditions of this assay, high molecular weight BAFF in cord
blood is recognized and inhibited by belimumab. In only one
cord sample did we detect a BAFF activity that was resistant to
belimumab and in good agreement with the percentage detected
by ELISA post SEC (Supplementary Figure 7). The result could
not be repeated because of insufficient amounts of sample. Taken
together, these results indicate that the high molecular weight
BAFF in cord blood is recognized by two antibodies that cannot
bind recombinant BAFF 60-mer.
DISCUSSION
The ability of BAFF to form 60-mer is a likely evolutionary
conserved feature, since the length and critical residues of
the flap region are conserved across species (Bossen et al.,
2008). Although the presence of mouse BAFF 60-mer in
BAFF transgenic and TACI-ko mice (Bossen et al., 2008) and
human BAFF 60-mer in conditioned medium of U937 cells
(Cachero et al., 2006) were reported, there is still no evidence
showing the existence of BAFF 60-mer in human. BAFF 60-
mer is different from BAFF 3-mer, not only in terms of size
and activity, but also with regards to recognition by different
antibodies. We took advantage of some of these differences to
develop test systems which are able to discriminate between
the activities of BAFF 3-mers and 60-mers. We also adapted
FIGURE 10 | High molecular weight cord blood BAFF is detected by BAFF ELISA also at pH 7.4. (A) A cord serum sample was size-fractionated by SEC. Fractions
were immediately analyzed by BAFF ELISA with a short capture time (30 min at 4◦C instead of 3 h at room temperature). (B) Same as panel (A), except that the
same cord serum sample was first depleted from endogenous BAFF and spiked with 5 ng/ml of recombinant, naturally cleaved BAFF 60-mer. (C) Naturally cleaved
recombinant BAFF 60-mer used in panel (A) (but not spiked in serum) was measured in the BAFF ELISA with capture steps at pH 5.5 or pH 7.4. (D) Same as panel
(C), but with recombinant His-BAFF 60-mer.
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FIGURE 11 | BAFF in cord blood is inhibited by belimumab, as measured in a cell-based assay that distinguishes BAFF 60-mer from BAFF 3-mer. Activities of
different forms of recombinant BAFF were monitored on BAFFR:Fas reporter cells in the presence of the following modifiers: (none, white circles), an activating
anti-BAFF monoclonal antibody (2.81, black circles), a TACI-Fc decoy receptor (atacicept, white squares) or a blocking anti-BAFF monoclonal antibody (belimumab,
black squares). (A) Flag-BAFF 3-mer. (B) Small molecular weight form (SEC fractions 15 + 16, 3-mer) of naturally processed WT BAFF in supernatants of transfected
293T cells. (C) Small molecular weight form (SEC fractions 15 + 16, 3-mer) of naturally processed BAFF with mutation H218A in the flap that prevents 60-mer
formation but not signaling through BAFFR. (D) Small molecular weight form (SEC fractions 15 + 16, 3-mer) of naturally processed BAFF with mutation E223K in the
flap region that prevents formation of 60-mer and signaling through BAFFR. (E) His-BAFF 60-mer. (F) High molecular weight form (SEC fractions 9 + 10, 60-mer) of
naturally processed WT BAFF in supernatants of transfected 293T cells. (G) Same as panel (F), but from another experiment. (H–L) Cord serum samples.
Experiments in panels (A–E) and (F + G) were performed five, three, two, two, five, and six times, respectively. Experiments in panels (H–L) were performed once.
Data for panels (A–F), (G–H), (I), and (J–L) were collected in independent experiments.
an ELISA to enable recognition of both 3-mer and 60-mer,
and not only 3-mer as is the case with the standard protocol.
A potentially criticisable aspect of the present study is the
use of the surrogate Fas signaling pathway in reporter cells,
but the sensitivity of this assay is high, with an EC50 of
0.05 pg/ml, or 0.005 pg/100 µl (Supplementary Figure 5A).
The molecular mass of BAFF 60-mer being 1,100 kDa, this is
equivalent to about 3,000 molecules of 60-mer per well, i.e.,
less than one 60-mer per reporter cell. Despite the sensitivity
of this assay, BAFF 60-mer remained undetected in adult
human sera, even in those of a patient with CVID and of
a patient with BAFFR-deficiency, in which circulating BAFF
levels are up to 500 times higher than in normal human
serum. Moreover, we found that serum is not a favorable
environment for BAFF 60-mer as it considerably, but not totally,
decreases its activity. BAFF 60-mer is known as a pH-sensitive
structure which dissociates into less active trimers at acidic pH
(Liu et al., 2002; Cachero et al., 2006). However, the 60-mer
inhibitory activity was not due to the pH, salt concentration
or other physical properties of human serum, as serum after
ultrafiltration contained no inhibitory activity. This observation
raised the question if BAFF 60-mers might be inhibited by
soluble extracellular domains of BAFFR, TACI, and/or BCMA,
all of which can be shed from the transmembrane forms of the
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receptor (Smulski and Eibel, 2018). However, this hypothesis
seems to be very unlikely. First, because this inhibitory activity
could not be depleted on immobilized Fc-BAFF; second, because
the inhibitory activity has a high molecular weight incompatible
with that of soluble receptors, third, because it is inconceivable
how soluble receptors should specifically target BAFF 60-mer
and not Fc-BAFF, and fourth, because atacicept, which is a
soluble dimeric form of TACI, binds to BAFF 60-mer without
dissociating it (Bossen et al., 2008). We found that the high
molecular weight, BAFF 60-mer dissociating activity could not
bind to Fc-BAFF, but we do not exclude the possibility that
it could bind specifically to BAFF 60-mer, for example if it
recognizes the flap-flap interface. When we realized that human
serum efficiently dissociated recombinant BAFF 60-mer into 3-
mer, we immediately thought that the residual activity was due
to the newly formed, less active BAFF 3-mer. This was, however,
not the case, as most of this residual activity had the size and
properties of BAFF 60-mer (Figure 4D and Supplementary
Figure 4B). Whether longer incubations in serum would have
destroyed this residual 60-mer activity, or whether there is a
fraction of serum-resistant recombinant BAFF 60-mer remains
to be investigated.
As BAFF and APRIL can heteromerize (Roschke et al., 2002;
Dillon et al., 2010; Schuepbach-Mallepell et al., 2015), and as
APRIL is devoid of the flap region that in BAFF is required for
3-mer to 3-mer interactions and 60-mer formation, it is possible
that low concentrations of BAFF-APRIL heteromers could
prevent 60-mer formation, explaining why all endogenous BAFF
in serum is detected as 3-mer. However, depletion of APRIL,
homomers and heteromers, with an anti-APRIL antibody did
not restore 60-mer formation. This alone is, however, insufficient
to discard the hypothesis that BAFF-APRIL heteromers would
interfere with 60-mer formation because we find that endogenous
BAFF 3-mer and BAFF 3-mer dissociated from recombinant
60-mer cannot re-associate into 60-mer, even after APRIL has
been removed. In this context, it still remains to be solved why
BAFF 3-mers originating from dissociated 60-mers and why
endogenous human BAFF cannot assemble into 60-mers even
in serum- or CSF-free conditions. An appealing hypothesis is
that the flap region (or other portions of BAFF that interact
with the flap) is modified by proteolytic processing. This would
explain specific loss of activity of BAFF 60-mer, but not other
forms of BAFF. Disruption of one flap out of 60 is in principle
sufficient to prevent 60-mer formation. However, the inhibitory
activity was not decreased when serum was first treated with
a mix of protease inhibitors (Supplementary Figure 2B). An
alternative mechanism could be a conformational change in
the flap region, such as the one observed in one of the BAFF
monomers in the crystal structure of the APRIL-BAFF-BAFF
heteromer (Schuepbach-Mallepell et al., 2015). The flap has a
defined structure that is virtually identical in all other available
crystal structures, including those where flap-flap interactions are
prevented by the Fab fragment of belimumab (Shin et al., 2018;
Vigolo et al., 2018). There is no doubt that the marked refolding
of the long loop of the “canonical” flap into the beta-hairpin
seen in the crystal structure of the heteromer would abrogate
60-mer formation.
To try and answer the main question of this study, namely
the detection of BAFF 60-mer in human body fluids, we
investigated different samples in search of one unable to
dissociate recombinant 60-mer. The implication of BAFF in
autoimmune diseases such as MS has been studied for years
(Kannel et al., 2015). While the transcript levels of BAFF are
clearly elevated in active MS lesions (Krumbholz et al., 2005),
data about CSF levels of BAFF in MS are not consistent. Some
studies found elevated BAFF (Ragheb et al., 2011; Wang et al.,
2012; Quan et al., 2013) in MS, others did not (Krumbholz et al.,
2005; Kowarik et al., 2012). The BAFF levels in the CSF are
influenced not only by local production, but also by consumption,
and soluble receptors. The CSF of MS patients contains a variable
number of B cells (Stangel et al., 2013) and it is plausible that
the CSF levels of BAFF are also determined by consumption of
B cells as are the blood levels of BAFF (Kreuzaler et al., 2012).
Further, in the CSF of MS patients, the soluble receptors sBCMA
and sTACI are elevated and function as decoys (Hoffmann et al.,
2015; Laurent et al., 2015).
Here we show that CSF from patients with MS are devoid
of BAFF 60-mer dissociating activity. Despite this, endogenous
BAFF in CSF was exclusively present as 3-mer, even after
purification on atacicept and size-fractionation at basic pH in
CSF-free conditions. About 80% of the proteins in the CSF
are derived from blood, 19% from the meninges and only 1%
from cells in the brain (Stangel et al., 2013). Since the CSF
from patients without inflammation in the brain contains BAFF
at a similar level as the CSF from MS patients (Krumbholz
et al., 2005; Kowarik et al., 2012), we would assume that
the majority of the BAFF in the CSF also in MS patients
is derived from blood, an hypothesis that would fit with
our observations that the CSF contains BAFF-3mer, and that
serum permanently transforms BAFF 60-mer into BAFF 3-
mer. In addition to CSF, we find that fetal calf serum do
not contain dissociating activity, while adult cow sera does.
A partially similar situation was observed in humans, with
high levels of dissociating activity in adult plasma or serum,
lower levels in the umbilical blood of neonates, and even lower
levels in two cord blood samples from pre-term babies. In
mice, we found no dissociating activity for BAFF 60-mer in
adult serum. The mouse BAFF gene contains an additional
30 amino acids at the N-terminus of the soluble form that
likely prevents efficient formation of 60-mer. We hypothesize
that a destabilization activity would not be required in mouse
serum if its goal is to prevent systemic action of BAFF 60-mer.
It was previously determined that administration of BAFF 3-
mer into BAFF-ko mice restored B cell populations, but not
expression of CD23, while administration of BAFF 60-mer
restored both, suggesting that BAFF 60-mer may fulfill specific
roles (Bossen et al., 2011).
Previous studies reported BAFF levels that were two-fold
higher in cord blood compared to maternal blood, although
these levels were not maintained in one- or four-month-old
babies, suggesting that BAFF could be produced by the placenta
(Bienertova-Vasku et al., 2015; Lundell et al., 2015). Interestingly,
BAFF was higher in cord blood of babies whose mothers were
exposed to dairy farm environment, correlating with more rapid
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B cell maturation later in childhood and decreased risk of
developing allergies (Lundell et al., 2015). Here we find that
(i) cord blood contains high levels of BAFF, greater than 10-
fold more than in adults, (ii) cord blood usually contains lower
levels of BAFF 60-mer dissociating activity, and (iii) cord blood
consistently contains up to 10% of a high molecular weight
form of BAFF with some, but not all properties of BAFF 60-
mer. In particular, this high molecular weight BAFF had a size
very similar to that of BAFF 60-mer, i.e., big but still included
into the active range of the size exclusion column. It was more
active than the fraction of BAFF 3-mer contained in the same
sample and could dissociate into 3-mer. These properties would
not be expected from a random protein aggregate. However,
our data strongly indicate that this high molecular weight BAFF
lacked two important features of recombinant BAFF 60-mer:
its pH sensitivity in the BAFF ELISA test, and its resistance to
inhibition by belimumab. Interestingly, both of these features
rely on the inaccessibility of antibody epitopes in BAFF 60-mer,
suggesting that they are already accessible, or become rapidly
accessible to antibodies in high molecular weight BAFF of cord
blood. We excluded the confounding effect of BAFF 60-mer
dissociating activity in serum by experiments of depletion and
spiking. In addition, specific depletion of APRIL and heteromers
did not decrease levels of high molecular weight BAFF, excluding
the hypothesis that it may contain BAFF APRIL heteromers
(unpublished observations). If high molecular weight BAFF in
cord blood is not comparable to recombinant BAFF 60-mer, then
what is its molecular nature? In a first scenario, BAFF 60-mer
would never form in vivo. High molecular weight BAFF would
be a complex of undefined nature, such as BAFF 3-mer bound to
auto-antibodies or to any other big-sized partner, which would,
however, not prevent BAFF activity. This would raise questions
of why non-neutralizing anti-BAFF auto-antibodies should be
present in cord blood, and similar hard-to-answer questions.
In a second scenario, BAFF 60-mer could be formed in vivo,
most probably locally after its synthesis by BAFF-producing
cells. BAFF 60-mer would not be meant to act systemically,
and thus would be dissociated into less active 3-mer. This
inactivation may proceed through less stable, easy-to-dissociate
BAFF 60-mer intermediates. Perhaps one or just a few flaps would
adopt a different conformation (Schuepbach-Mallepell et al.,
2015) that would render internal epitopes accessible. Binding of
just one antibody, or perhaps even a receptor, would quickly
dissociate the complex. Two different forms of recombinant
BAFF 60-mer, one made in bacteria (His-BAFF 60-mer) and
one made from naturally cleaved full-length BAFF expressed in
293T cells, seem to have different stabilities as judged by the
proportion of 3-mer released from these structures at pH 8.2
(e.g., Figures 3C, 4A, vs. Figures 3E, 9D–F). Thus, formation
of even less stable forms might be considered. Our data so far
do not allow distinguishing between these two models, and in
view of the minute amounts of BAFF available in these samples,
it might be technically challenging to do so. Perhaps more
information about a putative function of BAFF 60-mer in vivo
could come from genetic models in which BAFF 60-mer can
or cannot form. Our data, however, demonstrate that clinical
BAFF inhibitors will neutralize BAFF in the circulation: highly
active forms of BAFF 60-mer are unlikely to be predominant
in blood or in CSF, and even the high molecular weight form
of BAFF detected in cord blood can be inhibited by both
belimumab and atacicept.
In summary, with the help of sensitive tools developed for
the characterization of BAFF 60-mer in biologic fluids, we
demonstrated the exclusive presence of BAFF 3-mer in adult
human serum and CSF samples, and detected a high molecular
weight form of BAFF with some but not all properties of BAFF
60-mer in cord blood. In addition, an activity that dissociates
BAFF 60-mer into trimers was identified, which is higher in
adult serum than in cord blood. Advancing knowledge on the
endogenous forms of BAFF is relevant in view of its elevated
levels in various disorders (Cheema et al., 2001; Zhang et al., 2001;
McCarthy et al., 2013; Xin et al., 2013; Li et al., 2014; Kannel et al.,
2015; Salazar-Camarena et al., 2016; Steri et al., 2017) and the use
of BAFF antagonists with different ligand specificities in the clinic
or in clinical trials.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation, and
are available as a data set doi: 10.5281/zenodo.4141692.
ETHICS STATEMENT
The studies involving human participants were reviewed
and approved by Ethics Committee of the Medical
University of Vienna, Austria (EK Nr: 1845/2015). Human
systemic lupus erythematosus serum samples were from
patients who were enrolled in the randomized, double-
blind, APRIL-SLE trial, but before they received any
treatment with atacicept (ClinicalTrials.gov Identifier
NCT00624338). Cerebrospinal fluid (CSF) samples from
MS patients were provided by the Institute of Clinical
Neuroimmunology, Munich. This was approved by the
Ethical Committee of the Medical Faculty of Ludwig-
Maximilians-Universität München. Work with mice was
performed according to Swiss Federal Veterinary Office
guidelines, and under the authorization of the Office Vétérinaire
Cantonal du Canton de Vaud (authorization 1370.7 to
PS). Cow sera: this specific study had been approved by
the IACUC of Lower Saxony, the state veterinary office
Niedersächsisches Landesamt für Verbraucherschutz und
Lebensmittelsicherheit, Oldenburg, Germany (registration
number 33.42502-05-04A247).
AUTHOR CONTRIBUTIONS
PS and ME designed experiments. ME, LW, and PS performed
experiments. ME and PS wrote the manuscript. EM, HE, ODo,
ODi, HS, DS, DT, ÖY, and ES provided essential reagents. All
authors reviewed the results and approved the final version
of the manuscript.
Frontiers in Cell and Developmental Biology | www.frontiersin.org 17 November 2020 | Volume 8 | Article 577662
fcell-08-577662 November 3, 2020 Time: 14:20 # 18
Eslami et al. BAFF 60-mer and 60-mer-Dissociating Activities
FUNDING
This work was supported by the Swiss National Science
Foundation (grant 310030310030A_176256) to PS, the DFG (SFB
TR128), and the GMSI award 2018 (Merck KGaA) to EM.
ACKNOWLEDGMENTS
We thank Henry Hess (Merck KGaA, Darmstadt, Germany)
for the gift of atacicept, Hélène Maby-El-Hajjami (University
of Lausanne, Switzerland) for samples of lymphatic
exudate, and Tania Kümpfel (LMU Munich, Germany)
for CSF samples.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fcell.2020.
577662/full#supplementary-material
REFERENCES
Bienertova-Vasku, J., Zlamal, F., Tomandl, J., Hodicka, Z., Novak, J., Splichal, Z.,
et al. (2015). The presence of B-cell activating factor (BAFF) in umbilical cord
blood in both healthy and pre-eclamptic pregnancies and in human breast milk.
J. Reprod. Immunol. 109, 89–93. doi: 10.1016/j.jri.2014.12.003
Bossen, C., and Schneider, P. (2006). BAFF. APRIL and their receptors: structure,
function and signaling. Semin. Immunol. 18, 263–275. doi: 10.1016/j.smim.
2006.04.006
Bossen, C., Cachero, T. G., Tardivel, A., Ingold, K., Willen, L., Dobles, M., et al.
(2008). TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL
to support survival of activated B cells and plasmablasts. Blood 111, 1004–1012.
doi: 10.1182/blood-2007-09-110874
Bossen, C., Tardivel, A., Willen, L., Fletcher, C. A., Perroud, M., Beermann, F., et al.
(2011). Mutation of the BAFF furin cleavage site impairs B-cell homeostasis and
antibody responses. Eur. J. Immunol. 41, 787–797. doi: 10.1002/eji.201040591
Broggi, M. A. S., Maillat, L., Clement, C. C., Bordry, N., Corthesy, P., Auger,
A., et al. (2019). Tumor-associated factors are enriched in lymphatic exudate
compared to plasma in metastatic melanoma patients. J. Exp. Med. 216, 1091–
1107. doi: 10.1084/jem.20181618
Cachero, T. G., Schwartz, I. M., Qian, F., Day, E. S., Bossen, C., Ingold, K., et al.
(2006). Formation of virus-like clusters is an intrinsic property of the tumor
necrosis factor family member BAFF (B cell activating factor). Biochemistry 45,
2006–2013. doi: 10.1021/bi051685o
Cheema, G. S., Roschke, V., Hilbert, D. M., and Stohl, W. (2001). Elevated
serum B lymphocyte stimulator levels in patients with systemic immune-
based rheumatic diseases. Arthritis Rheum. 44, 1313–1319. doi: 10.1002/1529-
0131(200106)44:6<1313::aid-art223>3.0.co;2-s
Claudio, E., Brown, K., Park, S., Wang, H., and Siebenlist, U. (2002). BAFF-
induced NEMO-independent processing of NF-kappa B2 in maturing B cells.
Nat. Immunol. 3, 958–965. doi: 10.1038/ni842
Craxton, A., Draves, K. E., Gruppi, A., and Clark, E. A. (2005). BAFF regulates B
cell survival by downregulating the BH3-only family member Bim via the ERK
pathway. J. Exp. Med. 202, 1363–1374. doi: 10.1084/jem.20051283
Craxton, A., Magaletti, D., Ryan, E. J., and Clark, E. A. (2003). Macrophage- and
dendritic cell-dependent regulation of human B-cell proliferation requires the
TNF family ligand BAFF. Blood 16:16.
Dillon, S. R., Harder, B., Lewis, K. B., Moore, M. D., Liu, H., Bukowski, T. R., et al.
(2010). B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers
are elevated in the sera of patients with autoimmune disease and are neutralized
by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther.
12:R48.
Giordano, D., Kuley, R., Draves, K. E., Roe, K., Holder, U., Giltiay, N. V., et al.
(2020). BAFF Produced by Neutrophils and Dendritic Cells Is Regulated
Differently and Has Distinct Roles in Antibody Responses and Protective
Immunity against West Nile Virus. J. Immunol. 204, 1508–1520. doi: 10.4049/
jimmunol.1901120
Grell, M., Douni, E., Wajant, H., Lohden, M., Clauss, M., Maxeiner, B., et al. (1995).
The transmembrane form of tumor necrosis factor is the prime activating
ligand of the 80 kDa tumor necrosis factor receptor. Cell 83, 793–802. doi:
10.1016/0092-8674(95)90192-2
Hahn, B. H. (2013). Belimumab for systemic lupus erythematosus. N. Engl. J. Med.
368, 1528–1535.
Hahne, M., Kataoka, T., Schroter, M., Hofmann, K., Irmler, M., Bodmer, J. L., et al.
(1998). APRIL, a new ligand of the tumor necrosis factor family, stimulates
tumor growth. J. Exp.Med. 188, 1185–1190. doi: 10.1084/jem.188.6.1185
Hatada, E. N., Do, R. K., Orlofsky, A., Liou, H. C., Prystowsky, M., MacLennan,
I. C., et al. (2003). NF-kappa B1 p50 is required for BLyS attenuation of
apoptosis but dispensable for processing of NF-kappa B2 p100 to p52 in
quiescent mature B cells. J. Immunol. 171, 761–768. doi: 10.4049/jimmunol.
171.2.761
Hoffmann, F. S., Kuhn, P. H., Laurent, S. A., Hauck, S. M., Berer, K., Wendlinger,
S. A., et al. (2015). The immunoregulator soluble TACI is released by ADAM10
and reflects B cell activation in autoimmunity. J. Immunol. 194, 542–552. doi:
10.4049/jimmunol.1402070
Kannel, K., Alnek, K., Vahter, L., Gross-Paju, K., Uibo, R., and Kisand, K. V. (2015).
Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis:
A Sign of Treatment Outcome. PLoS One 10:e0143393. doi: 10.1371/journal.
pone.0143393
Kato, A., Truong-Tran, A. Q., Scott, A. L., Matsumoto, K., and Schleimer, R. P.
(2006). Airway epithelial cells produce B cell-activating factor of TNF family by
an IFN-beta-dependent mechanism. J. Immunol. 177, 7164–7172. doi: 10.4049/
jimmunol.177.10.7164
Kowalczyk-Quintas, C., Chevalley, D., Willen, L., Jandus, C., Vigolo, M., and
Schneider, P. (2018). Inhibition of Membrane-Bound BAFF by the Anti-
BAFF Antibody Belimumab. Front. Immunol. 9:2698. doi: 10.3389/fimmu.2018.
02698
Kowalczyk-Quintas, C., Schuepbach-Mallepell, S., Vigolo, M., Willen, L., Tardivel,
A., Smulski, C. R., et al. (2016). Antibodies That Block or Activate Mouse B
Cell Activating Factor of the Tumor Necrosis Factor (TNF) Family (BAFF).
Respectively, Induce B Cell Depletion or B Cell Hyperplasia. J. Biol. Chem. 291,
19826–19834. doi: 10.1074/jbc.m116.725929
Kowarik, M. C., Cepok, S., Sellner, J., Grummel, V., Weber, M. S., Korn, T., et al.
(2012). CXCL13 is the major determinant for B cell recruitment to the CSF
during neuroinflammation. J. Neuroinflammat. 9:93.
Kreuzaler, M., Rauch, M., Salzer, U., Birmelin, J., Rizzi, M., Grimbacher, B., et al.
(2012). Soluble BAFF levels inversely correlate with peripheral B cell numbers
and the expression of BAFF receptors. J. Immunol. 188, 497–503. doi: 10.4049/
jimmunol.1102321
Krumbholz, M., Faber, H., Steinmeyer, F., Hoffmann, L. A., Kumpfel, T., Pellkofer,
H., et al. (2008). Interferon-beta increases BAFF levels in multiple sclerosis:
implications for B cell autoimmunity. Brain 131, 1455–1463. doi: 10.1093/
brain/awn077
Krumbholz, M., Theil, D., Derfuss, T., Rosenwald, A., Schrader, F., Monoranu,
C. M., et al. (2005). BAFF is produced by astrocytes and up-regulated in multiple
sclerosis lesions and primary central nervous system lymphoma. J. Exp. Med.
201, 195–200. doi: 10.1084/jem.20041674
Laurent, S. A., Hoffmann, F. S., Kuhn, P. H., Cheng, Q., Chu, Y., Schmidt-Supprian,
M., et al. (2015). gamma-Secretase directly sheds the survival receptor BCMA
from plasma cells. Nat. Commun. 6:7333.
Li, W., Peng, X., Liu, Y., Liu, H., Liu, F., He, L., et al. (2014). TLR9 and BAFF: their
expression in patients with IgA nephropathy. Mol. Med. Rep. 10, 1469–1474.
doi: 10.3892/mmr.2014.2359
Liu, Y., Hong, X., Kappler, J., Jiang, L., Zhang, R., Xu, L., et al. (2003). Ligand-
receptor binding revealed by the TNF family member TALL-1. Nature 423,
49–56. doi: 10.1038/nature01543
Frontiers in Cell and Developmental Biology | www.frontiersin.org 18 November 2020 | Volume 8 | Article 577662
fcell-08-577662 November 3, 2020 Time: 14:20 # 19
Eslami et al. BAFF 60-mer and 60-mer-Dissociating Activities
Liu, Y., Xu, L., Opalka, N., Kappler, J., Shu, H. B., and Zhang, G. (2002). Crystal
structure of sTALL-1 reveals a virus-like assembly of TNF family ligands. Cell
108, 383–394. doi: 10.1016/s0092-8674(02)00631-1
Lundell, A. C., Hesselmar, B., Nordstrom, I., Adlerberth, I., Wold, A. E., and
Rudin, A. (2015). Higher B-cell activating factor levels at birth are positively
associated with maternal dairy farm exposure and negatively related to allergy
development. J. Aller. Clinic. Immunol. 136:e1073.
Mackay, F., and Schneider, P. (2009). Cracking the BAFF code. Nat. Rev. Immunol.
9, 491–502. doi: 10.1038/nri2572
Mackay, F., Schneider, P., Rennert, P., and Browning, J. (2003). BAFF and APRIL:
a tutorial on B cell survival. Annu. Rev. Immunol. 21, 231–264.
McCarthy, E. M., Lee, R. Z., Ni Gabhann, J., Smith, S., Cunnane, G., Doran,
M. F., et al. (2013). Elevated B lymphocyte stimulator levels are associated
with increased damage in an Irish systemic lupus erythematosus cohort.
Rheumatology 52, 1279–1284. doi: 10.1093/rheumatology/ket120
Merrill, J. T., Wallace, D. J., Wax, S., Kao, A., Fraser, P. A., Chang, P., et al.
(2018). Efficacy and Safety of Atacicept in Patients With Systemic Lupus
Erythematosus: Results of a Twenty-Four-Week. Multicenter, Randomized,
Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study. Arthritis
Rheumatol. 70, 266–276. doi: 10.1002/art.40360
Nys, J., Smulski, C. R., Tardivel, A., Willen, L., Kowalczyk, C., Donze, O., et al.
(2013). No evidence that soluble TACI induces signalling via membrane-
expressed BAFF and APRIL in myeloid cells. PLoS One 8:e61350. doi: 10.1371/
journal.pone.0061350
Pellkofer, H. L., Armbruster, L., Krumbholz, M., Titulaer, M. J., Verschuuren, J. J.,
Schumm, F., et al. (2008). Lambert-eaton myasthenic syndrome differential
reactivity of tumor versus non-tumor patients to subunits of the voltage-gated
calcium channel. J. Neuroimmunol. 204, 136–139. doi: 10.1016/j.jneuroim.
2008.08.002
Podzus, J., Kowalczyk-Quintas, C., Schuepbach-Mallepell, S., Willen, L., Staehlin,
G., Vigolo, M., et al. (2017). Ectodysplasin A in Biological Fluids and
Diagnosis of Ectodermal Dysplasia. J. Dent. Res. 96, 217–224. doi: 10.1177/
0022034516673562
Quan, C., Yu, H., Qiao, J., Xiao, B., Zhao, G., Wu, Z., et al. (2013).
Impaired regulatory function and enhanced intrathecal activation of B cells in
neuromyelitis optica: distinct from multiple sclerosis. Mult. Scler. 19, 289–298.
doi: 10.1177/1352458512454771
Ragheb, S., Li, Y., Simon, K., VanHaerents, S., Galimberti, D., De Riz, M., et al.
(2011). Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Mult. Scler.
17, 819–829. doi: 10.1177/1352458511398887
Roschke, V., Sosnovtseva, S., Ward, C. D., Hong, J. S., Smith, R., Albert, V.,
et al. (2002). BLyS and APRIL form biologically active heterotrimers that
are expressed in patients with systemic immune-based rheumatic diseases.
J. Immunol. 169, 4314–4321. doi: 10.4049/jimmunol.169.8.4314
Rosen, F. S., Eibl, M., Roifman, C., Fischer, A., Volanakis, J., Aiuti, F., et al.
(1999). Primary immunodeficiency diseases. Report of an IUIS Scientific
Committee. International Union of Immunological Societies. Clin. Exp.
Immunol. 118(Suppl. 1), 1–28. doi: 10.1046/j.1365-2249.1999.00109.x
Salazar-Camarena, D. C., Ortiz-Lazareno, P. C., Cruz, A., Oregon-Romero, E.,
Machado-Contreras, J. R., Munoz-Valle, J. F., et al. (2016). Association of BAFF.
APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell
subsets with clinical manifestations in systemic lupus erythematosus. Lupus 25,
582–592. doi: 10.1177/0961203315608254
Schiemann, B., Gommerman, J. L., Vora, K., Cachero, T. G., Shulga-Morskaya, S.,
Dobles, M., et al. (2001). An essential role for BAFF in the normal development
of B cells through a BCMA-independent pathway. Science 293, 2111–2114.
doi: 10.1126/science.1061964
Schneider, P. (2000). Production of recombinant TRAIL and TRAIL receptor:Fc
chimeric proteins. Meth. Enzymol. 322, 322–345.
Schneider, P., MacKay, F., Steiner, V., Hofmann, K., Bodmer, J. L., Holler, N., et al.
(1999). BAFF, a novel ligand of the tumor necrosis factor family, stimulates B
cell growth. J. Exp. Med. 189, 1747–1756. doi: 10.1084/jem.189.11.1747
Schneider, P., Willen, L., and Smulski, C. R. (2014). Tools and techniques to
study ligand-receptor interactions and receptor activation by TNF superfamily
members. Methods Enzymol. 545, 103–125. doi: 10.1016/b978-0-12-801430-1.
00005-6
Schuepbach-Mallepell, S., Das, D., Willen, L., Vigolo, M., Tardivel, A., Lebon,
L., et al. (2015). Stoichiometry of heteromeric BAFF and APRIL cytokines
dictates their receptor-binding and signaling propoerties. J. Biol. Chem. 290,
16330–16342. doi: 10.1074/jbc.m115.661405
Shin, W., Lee, H. T., Lim, H., Lee, S. H., Son, J. Y., Lee, J. U., et al. (2018). BAFF-
neutralizing interaction of belimumab related to its therapeutic efficacy for
treating systemic lupus erythematosus. Nat. Commun. 9:1200.
Smulski, C. R., and Eibel, H. (2018). BAFF and BAFF-Receptor in B Cell Selection
and Survival. Front. Immunol. 9:2285. doi: 10.3389/fimmu.2018.02285
Smulski, C. R., Kury, P., Seidel, L. M., Staiger, H. S., Edinger, A. K., Willen, L.,
et al. (2017). BAFF- and TACI-Dependent Processing of BAFFR by ADAM
Proteases Regulates the Survival of B Cells. Cell Rep. 18, 2189–2202. doi:
10.1016/j.celrep.2017.02.005
Stangel, M., Fredrikson, S., Meinl, E., Petzold, A., Stuve, O., and Tumani, H. (2013).
The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat.
Rev. Neurol. 9, 267–276. doi: 10.1038/nrneurol.2013.41
Steri, M., Orru, V., Idda, M. L., Pitzalis, M., Pala, M., Zara, I., et al. (2017).
Overexpression of the Cytokine BAFF and Autoimmunity Risk. N. Engl. J. Med.
376, 1615–1626.
Tom, R., Bisson, L., and Durocher, Y. (2008). Transfection of HEK293-EBNA1
Cells in Suspension with Linear PEI for Production of Recombinant Proteins.
CSH Protoc. 2008:rot4977.
Vigolo, M., Chambers, M. G., Willen, L., Chevalley, D., Maskos, K., Lammens,
A., et al. (2018). A loop region of BAFF controls B cell survival and regulates
recognition by different inhibitors. Nat. Commun. 9:1199.
Wang, H., Wang, K., Zhong, X., Qiu, W., Dai, Y., Wu, A., et al. (2012).
Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and
multiple sclerosis patients during relapse. J. Clin. Immunol. 32, 1007–1011.
doi: 10.1007/s10875-012-9709-9
Wang, L. C., Liu, Z. Y., Gambardella, L., Delacour, A., Shapiro, R., Yang, J., et al.
(2000). Regular articles: conditional disruption of hedgehog signaling pathway
defines its critical role in hair development and regeneration. J. Invest. Dermatol.
114, 901–908. doi: 10.1046/j.1523-1747.2000.00951.x
Warnatz, K., Salzer, U., Rizzi, M., Fischer, B., Gutenberger, S., Bohm, J.,
et al. (2009). B-cell activating factor receptor deficiency is associated
with an adult-onset antibody deficiency syndrome in humans. Proc.
Natl. Acad. Sci. U S A. 106, 13945–13950. doi: 10.1073/pnas.09035
43106
Xin, G., Shi, W., Xu, L. X., Su, Y., Yan, L. J., and Li, K. S. (2013). Serum BAFF
is elevated in patients with IgA nephropathy and associated with clinical
and histopathological features. J. Nephrol. 26, 683–690. doi: 10.5301/jn.
5000218
Zhang, J., Roschke, V., Baker, K. P., Wang, Z., Alarcon, G. S., Fessler,
B. J., et al. (2001). Cutting edge: a role for B lymphocyte stimulator in
systemic lupus erythematosus. J. Immunol. 166, 6–10. doi: 10.4049/jimmunol.
166.1.6
Zhukovsky, E. A., Lee, J. O., Villegas, M., Chan, C., Chu, S., and Mroske, C. (2004).
TNF ligands: is TALL-1 a trimer or a virus-like cluster? Nature 427, 413–414.
doi: 10.1038/427413a
Conflict of Interest: PS receives research funds from Merck KGaA for related
research, and has a licence agreement with Adipogen Life Sciences. ODo is
employee of Adipogen Life Sciences. ÖY is employee of Merck KGaA. ES was
employee of EMD Serono.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2020 Eslami, Meinl, Eibel, Willen, Donzé, Distl, Schneider, Speiser,
Tsiantoulas, Yalkinoglu, Samy and Schneider. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice. No
use, distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Cell and Developmental Biology | www.frontiersin.org 19 November 2020 | Volume 8 | Article 577662
His-BAFF-60mer [ng/ml]
10-210-4
BA
FF
R:
Fa
s
re
po
rte
r c
el
l
viv
ab
ilit
y
[%
]
0
100
10-110-3
Serum*
Serum* + TACI-Fc 
Serum* + BAFFR-Fc 
Serum* + BCMA-Fc 
Depletion
on:
TNFR2-Fc 
beads
Fc-BAFF 
beads
Serum* + TACI-Fc 
Serum* + BAFFR-Fc 
Serum* + BCMA-Fc 
plasma0
100
His-BAFF 60-mer [ng/ml]
BAFF 60-mer
spiked in:
FCS
1
RPMI 10% FCS
C
2
3
4
BA
FF
R:
Fa
s
re
po
rte
r
ce
ll v
iab
ilit
y [
%
]
human
sera
human
adult
adult
0.1 110-210-3Ø
Human serum
5
6
7
0
100
BA
FF
R:
Fa
sr
ep
or
te
r
ce
ll v
iab
ilit
y [
%
]
0.110-210-310-4
FCS
10% FCS
Human serum
FCS
Human serum
+ protease
inhibitors
His-BAFF 60-mer [ng/ml]
BA
BA
FF
R:
Fa
sr
ep
or
te
r
ce
ll v
iab
ilit
y [
%
]
0
100
10% FCS
FCS
Human serum
Human serum
at 56°C
0.110-210-310-4 1
His-BAFF 60-mer [ng/ml]
10 -1
110 -4
10 -2
10 -3
1010 -5
Purification on
atacicept
Purification on
belimumab
BA
FF
R
:F
as
re
po
rte
r c
el
l v
ia
bi
lit
y 
[%
]
100
0
His-BAFF 60-mer [ng/ml for input, equivalent
volume for FT and eluate]
PBS
H
epes
pH
 8.2
Fetalcalf
serum
N
orm
al hum
an
serum
Input
Eluate
FT
Input
Eluate
FT Belimumab
Atacicept
IP belim
um
abIP
 a
ta
cic
ep
t
FT
eluate eluate
input
PBS
pH 7.4
spike 60-mer (100 ng/ml)
depleted
human serum
depleted
FCS
Hepes buffer
pH 8.2
50% 50%
3 days
at 4°C
elution citrate
pH 2.7 - BSA,
buffer exchange
to Hepes pH 8.2
input
FT
10 -1
110 -4
10 -2
10 -3
1010 -5
100
0
100
0
100
0
A B C
D E
F G
H I

none
ata 100
beli
10000
beli
1000
beli 100
beli 10
beli 1
0
100
BA
FF
R:
Fa
s
re
po
rte
r
ce
ll v
iab
ilit
y [
%
]
0
100
BA
FF
R:
Fa
s
re
po
rte
r
ce
ll v
iab
ilit
y [
%
]
110-4
BAFF [ng/ml]
110-110-3 10-2
BAFF [ng/ml]
10
His-BAFF 60-mer
SEC fr 9-10 of
naturally cleaved
BAFF affinity-purified
on atacicpet
Norm
al RPM
I
RPM
I pH 8.2
A B
C D
10-110-3 10-2
BAFF inhibitor
(ng/m
l):
Naturally cleaved BAFF
SEC fr9+10 [fold dilution]
0
100
BAFF 60-mer
at dilution 1:
10 ng/ml
2.5 ng/ml
625 pg/ml
156 pg/ml
39 pg/ml
9.7 pg/ml
2.4 pg/ml
0 pg/mlB
AF
FR
:F
as
re
po
rte
r c
ell
via
bil
ity
 [%
]
Naturally cleaved BAFF
SEC fr9+10 + BAFF 3-mer
[fold dilution]
BAFF 60-mer BAFF 60-mer
+ belimumab
BAFF 60-mer
+ BAFF 3-mer
BAFF 60-mer
+ BAFF 3-mer
+ belimumab
Naturally cleaved BAFF
SEC fr9+10 [fold dilution]
Naturally cleaved BAFF
SEC fr9+10 + BAFF 3-mer
[fold dilution]
BAFF 3-mer
at dilution 1:
0 or 10 ng/m
l
0.
05
BA
FF
R:
Fa
sr
ep
or
te
r c
ell
via
bil
ity
 [%
]
BAFF 60-mer
at dilution 1:
1000 pg/ml
250 pg/ml
62 pg/ml
16 pg/ml
3.9 pg/ml
0.97 pg/ml
0.24 pg/ml
0.06 pg/ml
BAFF 3-mer
at dilution 1:
0 or 10 ng/m
l
BAFF 60-mer BAFF 60-mer
+ belimumab
BAFF 60-mer
+ BAFF 3-mer
BAFF 60-mer
+ BAFF 3-mer
+ belimumab
His-BAFF 60-mer
[fold dilution]
1
10
2
10
4
10
6 1010
3
10
5
His-BAFF 60-mer
+ BAFF 3-mer [fold dilution]
1
10
2
10
4
10
6 1010
3
10
51
10
2
10
4
10
6 1010
3
10
51
10
2
10
4
10
6 1010
3
10
5
His-BAFF 60-mer
+ BAFF 3-mer [fold dilution]
His-BAFF 60-mer
[fold dilution]
0.
1 0.
03
0.
08
1.
2
4.
5 0.
9
3.
0
1
10
2
10
4
10
6 1010
3
10
51
10
2
10
4
10
6 1010
3
10
51
10
2
10
4
10
6 1010
3
10
51
10
2
10
4
10
6 1010
3
10
5
A B
E F
C D
G H
0
His-BAFF 60-mer [ng/ml]
100
0
100
Naturally cleaved-BAFF
WT SEC fr 9,10 [ng/ml]
none
2.81
atacicept
belimumab
B
A
FF
R
:F
as
re
po
rte
r
ce
ll 
vi
ab
ili
ty
 [%
]
A B
E F
C
G
110 -1
10 -2
10 -3
10 -4
B
A
FF
R
:F
as
re
po
rte
r
ce
ll 
vi
ab
ili
ty
 [%
]
110 -1
10 -2
10 -3
10 -4
Fc-BAFF [ng/ml]
m
odifier of
B
A
FF activity
(at 100 ng/m
l)
D
H
Flag-BAFF 3-mer [ng/ml]
w
ith
hum
an
serum
no hum
an
serum
10110 -1
10 -2
10 -3
10110 -1
10 -2
10 -3
B C
none
2.81
atacicept
belimumab
modifiers of
BAFF activity
(at 100 ng/ml)
D E F
BAFF [ng/ml]
Normal human serum
10 -2
10 -3
10 -4
G
0
100
BA
FF
R:
Fa
sr
ep
or
te
r c
ell
via
bil
ity
 [%
]
A
110 -1
10 -2
10 -3
BAFFR-def serum #3
BAFF [ng/ml]
Pooled CSF
BAFF [ng/ml]
Cord serum #3
BAFF [ng/ml]
1
CVID serum
BAFF [ng/ml]
110 -2
BAFFR-def serum #2
BAFF [ng/ml]
0
100
BA
FF
R:
Fa
sr
ep
or
te
r c
ell
via
bil
ity
 [%
]
Flag-BAFF 3-mer [ng/ml]
101
BAFF 3-mer
10 -1
10 -1
10 -2
10 -3
10 -1
10 -2
10 -3
10 -1
10 -2
10 -3
10 -2
10 -3
10 -4




